Predictive value of 18F-FDG PET/CT metabolic parameters for lymph node metastasis of non-small cell lung cancer.

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-01-01 Epub Date: 2024-12-24 DOI:10.1080/17520363.2024.2443379

Xiaopeng Yu, Jianlin Wang, Liqun Huang, Long Xie, Yingrui Su

{"title":"Predictive value of 18F-FDG PET/CT metabolic parameters for lymph node metastasis of non-small cell lung cancer.","authors":"Xiaopeng Yu, Jianlin Wang, Liqun Huang, Long Xie, Yingrui Su","doi":"10.1080/17520363.2024.2443379","DOIUrl":null,"url":null,"abstract":"Background: Lymph node metastasis is closely associated with the prognosis of patients with non-small cell lung cancer (NSCLC). This study aimed to evaluate the role of preoperative 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) parameters in mediastinal lymph node metastasis in NSCLC.Methods: One hundred patients with NSCLC who underwent surgery, systematic lymph node dissection, who had undergone 18FFDG PET/CT for initial staging were divided into two groups: lymph node metastasis and non-metastasis. The maximum standardized uptake value (SUVmax), average standardized uptake value (SUVmean), SUV in the liver (SURliver), mediastinal blood pool (SURblood), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were detected in both groups. Receiver operating characteristic (ROC) curves were used to evaluate the parameters for predicting the diagnostic efficacy.Results: The SUVmax, SUVmean, SURblood, SURliver, MTV, and TLG were higher in the group with lymph node metastasis than in the group without lymph node metastasis. The ROC analysis showed that 18F-FDG PET/CT demonstrated acceptable predictive ability with AUC of 0.964 (95% CI, 0.930-0.998).Conclusions: The relative 18F-FDG PET/CT primary uptake and substitution parameters showed acceptable predictive efficacy for mediastinal lymph node metastasis in patients with NSCLC. Additional, SURblood has potential for clinical application.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"35-41"},"PeriodicalIF":1.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11749359/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2024.2443379","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/24 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Lymph node metastasis is closely associated with the prognosis of patients with non-small cell lung cancer (NSCLC). This study aimed to evaluate the role of preoperative 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) parameters in mediastinal lymph node metastasis in NSCLC.

Methods: One hundred patients with NSCLC who underwent surgery, systematic lymph node dissection, who had undergone 18FFDG PET/CT for initial staging were divided into two groups: lymph node metastasis and non-metastasis. The maximum standardized uptake value (SUVmax), average standardized uptake value (SUVmean), SUV in the liver (SURliver), mediastinal blood pool (SURblood), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were detected in both groups. Receiver operating characteristic (ROC) curves were used to evaluate the parameters for predicting the diagnostic efficacy.

Results: The SUVmax, SUVmean, SURblood, SURliver, MTV, and TLG were higher in the group with lymph node metastasis than in the group without lymph node metastasis. The ROC analysis showed that 18F-FDG PET/CT demonstrated acceptable predictive ability with AUC of 0.964 (95% CI, 0.930-0.998).

Conclusions: The relative 18F-FDG PET/CT primary uptake and substitution parameters showed acceptable predictive efficacy for mediastinal lymph node metastasis in patients with NSCLC. Additional, SURblood has potential for clinical application.

查看原文本刊更多论文

18F-FDG PET/CT代谢参数对非小细胞肺癌淋巴结转移的预测价值

背景：淋巴结转移与非小细胞肺癌（NSCLC）患者的预后密切相关。本研究旨在评价术前18f -氟脱氧葡萄糖（FDG）正电子发射断层扫描/计算机断层扫描（PET/CT）参数在非小细胞肺癌纵隔淋巴结转移中的作用。方法：将100例行手术、系统淋巴结清扫并行18FFDG PET/CT初始分期的非小细胞肺癌患者分为淋巴结转移组和非转移组。检测两组患者最大标准化摄取值（SUVmax）、平均标准化摄取值（SUVmean）、肝脏内SUV （SURliver）、纵隔血池（SURblood）、代谢肿瘤体积（MTV）、病灶糖酵解总量（TLG）。采用受试者工作特征（ROC）曲线评价预测诊断效果的参数。结果：有淋巴结转移组的SUVmax、SUVmean、SURblood、SURliver、MTV、TLG均高于无淋巴结转移组。ROC分析显示，18F-FDG PET/CT具有较好的预测能力，AUC为0.964 （95% CI, 0.930-0.998）。结论：相对18F-FDG PET/CT初始摄取和替代参数对NSCLC患者纵隔淋巴结转移具有可接受的预测效果。此外，SURblood具有临床应用的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.